Anti-tumour activity and toxicological studies of combination treatment of Orthosiphon stamineus and gemcitabine on pancreatic xenograft model

Figure 5 Tumour necrosis percentage in tumour tissues stained with haematoxylin and eosin. A: Untreated group; B: Gemcitabine (10 mg/kg per 3 d); C: Orthosiphon stamineus (O.s) (200 mg/kg per day); D: O.s (200 mg/kg per day) + gemcitabine (10 mg/kg per 3 d); E: O.s (400 mg/kg per day); F: O.s (400 mg/kg per day) + gemcitabine (10 mg/kg per 3 d); G: Estimated marginal means of necrosis. Combination treatment of 400 mg/kg C5EOSEW5050ESA with gemcitabine synergistically inhibited tumour necrosis compared to a single treatment. Arrows indicate the necrotic area in tumour sections. Error bars represent standard deviations. Statistics analysis (two-way ANOVA, n = 6 animals per group) using SPSS software. O.s: Orthosiphon stamineus.